סטאבניר

Country: Iżrael

Lingwa: Ebrajk

Sors: Ministry of Health

Ingredjent attiv:

PRAVASTATIN SODIUM 40 MG

Disponibbli minn:

BIOAVENIR LTD

Kodiċi ATC:

C10AA03

Għamla farmaċewtika:

TABLETS

Rotta amministrattiva:

PER OS

Manifatturat minn:

WEST PHARMA- PROD. DE ESPEC. FARMACEUT.S.A.

Grupp terapewtiku:

PRAVASTATIN

Indikazzjonijiet terapewtiċi:

Pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . Pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *Primary prevention of coronary events: In hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - Reduce the risk of myocardial infarcton. - Reduce the risk for revascularization. - Reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *Secondary prevention of cardiovascular events: Atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior MI Pravastatin is indicated to: - Slow the progression of coronary atherosclerosis. - Reduce the risk of acute coronary events. Myocardial infa

Data ta 'l-awtorizzazzjoni:

2013-05-01